H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

I-Mab (NASDAQ:IMAB – Free Report) had its price objective lowered by HC Wainwright from $8.00 to $7.00 in a research report sent to investors on Friday morning,Benzinga reports. The brokerage ...

HC Wainwright reiterated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS – Free Report) in a report released on ...

H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...

H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright & Co., LLC ("HCW") announces a significant milestone, securing its #1 ranking for the 40th consecutive quarter in PlacementTracker's Market League Tables by transaction volume. "This ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on Benitec BioPharma (NASDAQ:BNTC) shares, maintaining a $28.00 price target. The stock has shown remarkable momentum, delivering a 225% return over ...

If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.

Fintel reports that on March 18, 2025, HC Wainwright & Co. initiated coverage of Alpha Cognition (NasdaqCM:ACOG) with a Buy recommendation. There are 26 funds or institutions reporting positions ...

On Monday, H.C. Wainwright reaffirmed its Buy rating and $6.00 price target for Veritone (NASDAQ:VERI), a $116 million market cap company currently trading at $2.61, following the company’s ...